Karl D. Lewis, MD - Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:13.033114
Go online to PeerView.com/TPR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in basal cell carcinoma (BCC) discusses the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures are linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly illustrate how oncologists can adapt their current practice and offer the power of immune-based treatment to patients with BCC. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanistic rationale and potential clinical role of immune checkpoint inhibitors in the treatment of basal cell carcinoma, Summarize clinical evidence on the use of checkpoint inhibitors in patients with locally advanced or metastatic basal cell carcinoma, including in patients progressing on prior therapy, Integrate immunotherapy into the management of patients with basal cell carcinoma in consultation with the wider management team, Recognize the spectrum of immune-related adverse events associated with the use of immunotherapy in the basal cell carcinoma setting.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education